AR125356A1 - Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4 - Google Patents

Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4

Info

Publication number
AR125356A1
AR125356A1 ARP220100959A ARP220100959A AR125356A1 AR 125356 A1 AR125356 A1 AR 125356A1 AR P220100959 A ARP220100959 A AR P220100959A AR P220100959 A ARP220100959 A AR P220100959A AR 125356 A1 AR125356 A1 AR 125356A1
Authority
AR
Argentina
Prior art keywords
inhibitor
combination
checkpoint inhibitor
ctla4 checkpoint
ctla4
Prior art date
Application number
ARP220100959A
Other languages
English (en)
Spanish (es)
Inventor
Gianluca Fossati
Flavio Leoni
Pietro Samuele Pozzi
Elisabetta Galbiati
Christian Steinkuhler
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of AR125356A1 publication Critical patent/AR125356A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP220100959A 2021-04-20 2022-04-18 Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4 AR125356A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4

Publications (1)

Publication Number Publication Date
AR125356A1 true AR125356A1 (es) 2023-07-12

Family

ID=76808052

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100959A AR125356A1 (es) 2021-04-20 2022-04-18 Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4

Country Status (17)

Country Link
US (1) US20240207228A1 (enExample)
EP (1) EP4326259A1 (enExample)
JP (1) JP7902198B2 (enExample)
KR (1) KR20230172001A (enExample)
CN (1) CN117177745A (enExample)
AR (1) AR125356A1 (enExample)
AU (1) AU2022262199A1 (enExample)
BR (1) BR112023021125A2 (enExample)
CA (1) CA3213275A1 (enExample)
CL (1) CL2023002894A1 (enExample)
CO (1) CO2023013780A2 (enExample)
IL (1) IL307649A (enExample)
IT (1) IT202100009926A1 (enExample)
MX (1) MX2023012030A (enExample)
PE (1) PE20242078A1 (enExample)
TW (1) TW202308609A (enExample)
WO (1) WO2022223543A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119424649A (zh) * 2024-02-29 2025-02-14 中山大学附属第一医院 假体周围感染治疗靶点及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190022203A1 (en) 2016-01-11 2019-01-24 Turnstone Limited Partnership Oncolytic virus and checkpoint inhibitor combination therapy
IT201700041723A1 (it) * 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6

Also Published As

Publication number Publication date
CN117177745A (zh) 2023-12-05
CL2023002894A1 (es) 2024-03-15
TW202308609A (zh) 2023-03-01
CO2023013780A2 (es) 2023-11-10
WO2022223543A1 (en) 2022-10-27
IL307649A (en) 2023-12-01
US20240207228A1 (en) 2024-06-27
IT202100009926A1 (it) 2022-10-20
MX2023012030A (es) 2023-10-24
BR112023021125A2 (pt) 2023-12-12
JP2024515100A (ja) 2024-04-04
PE20242078A1 (es) 2024-10-18
EP4326259A1 (en) 2024-02-28
CA3213275A1 (en) 2022-10-27
KR20230172001A (ko) 2023-12-21
AU2022262199A1 (en) 2023-09-21
JP7902198B2 (ja) 2026-08-07

Similar Documents

Publication Publication Date Title
MX2021010544A (es) Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
ECSP20052897A (es) Inhibidores de cd73
CY1124078T1 (el) Συνθεσεις που περιλαμβανουν αναστολεα λυσινης ειδικης απομεθυλασης-1 που εχει δακτυλιο πυριμιδινης και χρηση αυτων στη θεραπεια καρκινου
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
JOP20210050A1 (ar) معدلات تعبير pnpla3
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2019001337A1 (es) Formulaciones farmacéuticas.
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
AR059066A1 (es) Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CL2018003361A1 (es) Uso médico de una combinación o composición farmacéutica.
CL2022000214A1 (es) Inhibidores de enzimas
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
CO2022000270A2 (es) Inhibidores de enzimas
MX2022003010A (es) Tratamiento de la emr mediante cambio de terapia.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
CO2023013780A2 (es) Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
MX2020007375A (es) Terapias de combinacion para el tratamiento de carcinoma hepatocelular.